PMID- 37855184
OWN - NLM
STAT- MEDLINE
DCOM- 20231117
LR  - 20231121
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 102
IP  - 6
DP  - 2023 Nov
TI  - Angiographic patterns of restenosis after drug-coated balloon angioplasty for 
      femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy.
PG  - 1114-1121
LID - 10.1002/ccd.30856 [doi]
AB  - AIM: The aim of the current study sought to investigate the angiographic patterns 
      of restenosis after drug-coated balloon (DCB) angioplasty for femoropopliteal 
      (FP) lesions and which repeat endovascular therapy (EVT) for DCB restenosis would 
      provide more freedom from recurrent restenosis. METHODS: This retrospective 
      multicenter study included 119 limbs (chronic limb-threatening ischemia [CLTI]: 
      55%, lesion length: 136.9 +/- 89.6 mm, chronic total occlusion: 25%) of 95 patients 
      (diabetes mellitus: 70%, hemodialysis: 56%) who were diagnosed with DCB 
      restenosis between January 2018 and December 2019. The cases were classified into 
      three groups based on angiographic patterns of restenosis: Class I: focal lesions 
      </=50 mm, Class II: diffuse lesions >50 mm, and Class III: totally occluded 
      lesions. The DCB restenosis patterns and frequency and predictors of recurrent 
      restenosis after repeated EVT (re-EVT) were investigated. RESULTS: The mean 
      follow-up duration was 29.8 +/- 9.5 months. Groups I, II, and III comprised of 30 
      (25.2%), 55 (46.2%), and 34 (29.0%) cases, respectively. The overall rate of 
      1-year freedom from recurrent restenosis was 58.2%. One-year rate of freedom from 
      recurrent restenosis after repeat DCB was not statistically different from that 
      after scaffolding (71.1% vs. 74.6%, respectively, p = 0.911); however, it was 
      significantly better than that after noncoated balloon angioplasty (repeat DCB 
      vs. noncoated balloon angioplasty: 71.1% vs. 25.7%, respectively, p < 0.001). 
      Multivariate analysis demonstrated that CLTI (hazard ratio [HR]: 5.15, p < 0.001) 
      and re-EVT with noncoated balloon (HR: 3.16, p < 0.001) were significantly 
      associated with recurrent restenosis; however, Class III pattern of DCB 
      restenosis was not associated with recurrent restenosis (HR: 1.04, p = 0.918). 
      CONCLUSIONS: This study revealed the angiographic patterns of restenosis after 
      DCB therapy for FP lesions and the 1-year rate of recurrent restenosis after 
      repeat revascularization. Repeat DCB therapy demonstrated acceptable 1-year 
      recurrent restenosis rates.
CI  - (c) 2023 Wiley Periodicals LLC.
FAU - Higashino, Naoko
AU  - Higashino N
AUID- ORCID: 0000-0001-7755-4130
AD  - Kansai Rosai Hospital, Cardiovascular Center, Amagasaki, Hyogo, Japan.
FAU - Iida, Osamu
AU  - Iida O
AUID- ORCID: 0000-0001-6829-7304
AD  - Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.
FAU - Ishihara, Takayuki
AU  - Ishihara T
AUID- ORCID: 0000-0002-7505-0817
AD  - Kansai Rosai Hospital, Cardiovascular Center, Amagasaki, Hyogo, Japan.
FAU - Hata, Yosuke
AU  - Hata Y
AD  - Kansai Rosai Hospital, Cardiovascular Center, Amagasaki, Hyogo, Japan.
FAU - Toyoshima, Taku
AU  - Toyoshima T
AUID- ORCID: 0000-0003-1590-5227
AD  - Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.
FAU - Tsukizawa, Tomofumi
AU  - Tsukizawa T
AUID- ORCID: 0000-0003-3947-2892
AD  - Department of Cardiology, Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan.
FAU - Nishian, Kunihiko
AU  - Nishian K
AD  - Department of Cardiology, Morinomiya Hospital, Morinomiya, Osaka, Japan.
FAU - Fujihara, Masahiko
AU  - Fujihara M
AUID- ORCID: 0000-0002-7001-9220
AD  - Department of Cardiology, Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan.
FAU - Kawasaki, Daizo
AU  - Kawasaki D
AD  - Department of Cardiology, Morinomiya Hospital, Morinomiya, Osaka, Japan.
FAU - Mano, Toshiaki
AU  - Mano T
AD  - Kansai Rosai Hospital, Cardiovascular Center, Amagasaki, Hyogo, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20231019
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Coated Materials, Biocompatible)
SB  - IM
MH  - Humans
MH  - Popliteal Artery/diagnostic imaging
MH  - Treatment Outcome
MH  - Femoral Artery/diagnostic imaging
MH  - *Angioplasty, Balloon/adverse effects
MH  - Prognosis
MH  - *Endovascular Procedures
MH  - Coated Materials, Biocompatible
MH  - *Peripheral Arterial Disease/diagnostic imaging/therapy
MH  - Vascular Patency
OTO - NOTNLM
OT  - BALD-balloon
OT  - PAD-peripheral arterial disease
OT  - REST-restenosis
OT  - drug coated/eluting
EDAT- 2023/10/19 06:46
MHDA- 2023/11/17 15:28
CRDT- 2023/10/19 05:37
PHST- 2023/08/19 00:00 [revised]
PHST- 2023/04/26 00:00 [received]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2023/11/17 15:28 [medline]
PHST- 2023/10/19 06:46 [pubmed]
PHST- 2023/10/19 05:37 [entrez]
AID - 10.1002/ccd.30856 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2023 Nov;102(6):1114-1121. doi: 10.1002/ccd.30856. 
      Epub 2023 Oct 19.